Stockreport

SAGE's Huntington's Disease Study Meets Primary Endpoint [Yahoo! Finance]

Acrivon Therapeutics, Inc.  (ACRV) 
PDF potential treatment for patients with cognition dysfunction caused by Huntington's disease (HD), met its primary endpoint. Shares of the company were however down 2.8% o [Read more]